A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis
Status:
Withdrawn
Trial end date:
2018-02-27
Target enrollment:
Participant gender:
Summary
The study drug (VLX103) is being developed for the treatment of Alcoholic Steatohepatitis and
other liver diseases. Alcoholic Steatohepatitis is an inflammatory (associated with
irritation, swelling and cell damage) disease that affects the liver. It is associated with
heavy and chronic intake of alcohol and presence of fat in the liver. Signs and symptoms
often include fever, yellowing of the skin, nausea and impairment of liver function.
The main objective of this study is to evaluate the safety, pharmacodynamics (what the drug
does to the body) and pharmacokinetics (how the drug is handled by the human body, like
absorption and elimination) of increasing doses of VLX103 in subjects with moderate Alcoholic
Steatohepatitis. In other words, we will evaluate how your body tolerates VLX103 at a
specific dose and the effects that this VLX103 dose has on your liver and your body in
general. The secondary objectives of this study are to evaluate if VLX103 has the potential
to treat Alcoholic Steatohepatitis patients, to determine the maximum dose that can be
tolerated, and to measure the levels of VLX103 in your blood at different time points during
the study.
VLX103 is an experimental drug. Experimental means that the drug has not been approved by the
Food and Drug Administration (FDA) for the treatment of Alcoholic Steatohepatitis. The active
ingredient in VLX103, pentamidine, is approved for treating parasitic (microorganisms)
infections. Pentamidine is currently approved and marketed in about 20 countries, including
the United States, for use by injection (administered by a syringe) and by inhalation
(administered by a nebulizer) for other health conditions. However, VLX103 is the first oral
form of pentamidine being developed, and is administered by mouth as an oral tablet.
Phase:
Phase 1
Details
Lead Sponsor:
Gyongyi Szabo
Collaborators:
National Institute on Alcohol Abuse and Alcoholism (NIAAA) The Cleveland Clinic University of Louisville University of Texas Southwestern Medical Center